{"nctId":"NCT01524783","briefTitle":"Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)","startDateStruct":{"date":"2012-03-30","type":"ACTUAL"},"conditions":["Advanced NET of GI Origin","Advanced NET of Lung Origin","Neuroendocrine Tumors"],"count":302,"armGroups":[{"label":"Everolimus + BSC","type":"EXPERIMENTAL","interventionNames":["Drug: Everolimus","Other: Best suportive care (BSC)"]},{"label":"Placebo + BSC","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Other: Best suportive care (BSC)"]}],"interventions":[{"name":"Everolimus","otherNames":["RAD001"]},{"name":"Placebo","otherNames":[]},{"name":"Best suportive care (BSC)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically confirmed, well differentiated (G1 or G2), advanced (unresectable or metastatic), neuroendocrine tumor of GI or lung origin\n* No history of and no active symptoms related to carcinoid syndrome\n* In addition to treatment-naive patients, patients previously treated with SSA, Interferon (IFN), one prior line of chemotherapy, and/or PRRT were allowed into the study. Pretreated patients had to have progressed on or after the last treatment\n* Radiological documented disease progression within 6 months prior to randomization\n* Measurable disease\n* WHO performance status ≤1\n* Adequate bone marrow, liver and renal function\n\nExclusion Criteria:\n\n* Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, large cell neuroendocrine carcinoma and small cell carcinoma\n* Patients with pancreatic NET or NET of origins other than GI or Lung\n* Patients with history of or active symptoms of carcinoid syndrome (e.g. flushing, diarrhea)\n* Patients with more than one line of prior chemotherapy\n* Prior targeted therapy\n* Hepatic intra-arterial embolization within the last 6 months. Cryoablation or radiofrequency ablation of hepatic metastases within 2 months of randomization\n* Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, deforolimus)\n* Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)\n* Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus\n* Uncontrolled diabetes mellitus as defined by HbA1c \\>8% despite adequate therapy\n* Patients who had any severe and/or uncontrolled medical conditions such as:\n\n  * unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to randomization, serious uncontrolled cardiac arrhythmia\n  * active or uncontrolled severe infection\n  * liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA)\n* Chronic treatment with corticosteroids or other immunosuppressive agents\n* Known history of HIV seropositivity\n* Pregnant or nursing (lactating) women\n\nOther protocol-defined inclusion/exclusion criteria might apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment","description":"PFS is defined as the time from randomization to the date of the first documented tumor progression or death from any cause, whichever comes first.\n\nProgression was defined using modified RECIST 1.0 and as per central radiology assessment as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. Progression was assessed by cat scan (CT) and/or magnetic resonance imaging (MRI).\n\nFor participants who had not progressed or died at the analysis cut-off date, PFS was censored at the date of the last adequate tumor evaluation date. An adequate tumour assessment is a tumour assessment with an overall response other than unknown.\n\nThe percentage event-free probability estimate is the estimated probability that a patient will remain event-free in PFS up to the specified time point.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null},{"groupId":"OG001","value":"74.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"49.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"40.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":null},{"groupId":"OG001","value":"35.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"31.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"28.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","spread":null},{"groupId":"OG001","value":"26.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"24.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"17.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"17.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"17.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from the date of randomization to date of death due to any cause. If a death had not been observed by the date of analysis cut-off, then OS was censored at the date of last contact. All participants randomized to placebo arm who crossed over to everolimus were censored.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null},{"groupId":"OG001","value":"41.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) as Per Modified RECIST 1.0 According to Central Evaluation","description":"ORR is defined as the proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR), according to central evaluation and as per modified RECIST 1.0.\n\nCR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR) Based on Modified RECIST 1.0 and as Per Central Radiology Assessment","description":"DCR is defined as the proportion of subjects with best overall response of CR or PR or stable disease based on modified RECIST 1.0 and as per central radiology assessment.\n\nCR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.\n\nStable disease: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.4","spread":null},{"groupId":"OG001","value":"64.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Definitive Deterioration in Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire Total Score","description":"FACT-G is a self-assessed health-related quality of life questionnaire. The questionnaire is comprised of 27 questions examining physical, social/family, emotional, and functional well-being. Participants responded to the items on a five-point scale, ranging from 0: \"Not at all\" to 4: \"Very much.\" The total score ranges from 0 to 108, with higher scores indicating a better patient-reported outcome/quality of life.\n\nDefinitive deterioration is defined as a decrease in the total score by at least 7 points compared to baseline with no further improvement.\n\nDeath was considered as worsening of the FACT-G total score if it occurred close to the last available assessment, where \"close\" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.01","spread":null},{"groupId":"OG001","value":"9.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Chromogranin A (CgA) Levels","description":"CgA is a potential biomarker for tumor response. Blood samples were collected for assessment of CgA levels. Change from Baseline at a particular visit was calculated as the CgA level at that visit minus Baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"434.8","spread":"2306.70"},{"groupId":"OG001","value":"1154.3","spread":"9083.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162.3","spread":"2550.65"},{"groupId":"OG001","value":"2697.6","spread":"19956.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"396.7","spread":"2401.78"},{"groupId":"OG001","value":"1176.0","spread":"3322.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"263.5","spread":"2946.76"},{"groupId":"OG001","value":"1450.4","spread":"4825.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162.1","spread":"2464.47"},{"groupId":"OG001","value":"3640.1","spread":"12653.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"253.2","spread":"3487.27"},{"groupId":"OG001","value":"1783.9","spread":"5399.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"587.2","spread":"4861.35"},{"groupId":"OG001","value":"1350.3","spread":"5701.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"508.5","spread":"6102.61"},{"groupId":"OG001","value":"2000.7","spread":"6362.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":"4905.17"},{"groupId":"OG001","value":"180.9","spread":"383.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"511.4","spread":"6180.67"},{"groupId":"OG001","value":"207.6","spread":"403.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"552.8","spread":"4173.44"},{"groupId":"OG001","value":"140.6","spread":"328.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1326.2","spread":"8718.92"},{"groupId":"OG001","value":"129.0","spread":"326.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1196.2","spread":"7737.76"},{"groupId":"OG001","value":"124.2","spread":"452.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1920.6","spread":"11250.07"},{"groupId":"OG001","value":"134.9","spread":"346.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1722.0","spread":"13155.03"},{"groupId":"OG001","value":"120.9","spread":"415.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3811.0","spread":"26656.45"},{"groupId":"OG001","value":"141.6","spread":"281.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1413.3","spread":"9588.68"},{"groupId":"OG001","value":"222.6","spread":"333.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239.5","spread":"2318.79"},{"groupId":"OG001","value":"233.7","spread":"400.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3256.5","spread":"19395.40"},{"groupId":"OG001","value":"210.9","spread":"522.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5421.0","spread":"32471.22"},{"groupId":"OG001","value":"286.3","spread":"425.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4379.9","spread":"28302.84"},{"groupId":"OG001","value":"175.4","spread":"575.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"571.2","spread":"2694.44"},{"groupId":"OG001","value":"-9.4","spread":"473.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"765.5","spread":"2913.15"},{"groupId":"OG001","value":"63.7","spread":"477.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"984.6","spread":"3379.28"},{"groupId":"OG001","value":"146.5","spread":"468.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"935.3","spread":"2961.60"},{"groupId":"OG001","value":"-12.7","spread":"399.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1466.4","spread":"4257.03"},{"groupId":"OG001","value":"-21.7","spread":"285.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2245.8","spread":"6077.99"},{"groupId":"OG001","value":"215.9","spread":"293.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2817.0","spread":"7786.28"},{"groupId":"OG001","value":"514.5","spread":"661.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2951.8","spread":"6745.06"},{"groupId":"OG001","value":"99.6","spread":"92.91"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Neuron Specific Enolase (NSE) Levels","description":"NSE is a potential biomarker for tumor response. Blood samples were collected for assessment of NSE levels. Change from Baseline at a particular visit was calculated as the NSE level at that visit minus Baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"5.21"},{"groupId":"OG001","value":"-2.2","spread":"39.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"8.71"},{"groupId":"OG001","value":"-4.2","spread":"36.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"8.37"},{"groupId":"OG001","value":"15.5","spread":"163.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"8.34"},{"groupId":"OG001","value":"4.1","spread":"19.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"6.21"},{"groupId":"OG001","value":"5.3","spread":"18.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"8.99"},{"groupId":"OG001","value":"6.7","spread":"23.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"6.37"},{"groupId":"OG001","value":"0.4","spread":"9.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"14.24"},{"groupId":"OG001","value":"3.1","spread":"8.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"15.11"},{"groupId":"OG001","value":"2.0","spread":"5.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"6.48"},{"groupId":"OG001","value":"1.2","spread":"4.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"5.10"},{"groupId":"OG001","value":"1.2","spread":"4.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"9.20"},{"groupId":"OG001","value":"0.6","spread":"4.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"5.82"},{"groupId":"OG001","value":"0.7","spread":"4.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"18.56"},{"groupId":"OG001","value":"0.9","spread":"5.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"8.19"},{"groupId":"OG001","value":"0.1","spread":"3.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"23.22"},{"groupId":"OG001","value":"0.9","spread":"3.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"4.68"},{"groupId":"OG001","value":"1.9","spread":"4.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"4.46"},{"groupId":"OG001","value":"0.7","spread":"3.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"5.11"},{"groupId":"OG001","value":"0.6","spread":"3.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"10.15"},{"groupId":"OG001","value":"0.7","spread":"2.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"33.13"},{"groupId":"OG001","value":"0.1","spread":"3.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"3.89"},{"groupId":"OG001","value":"0.6","spread":"2.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"7.24"},{"groupId":"OG001","value":"0.1","spread":"3.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"5.96"},{"groupId":"OG001","value":"0.0","spread":"2.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"3.79"},{"groupId":"OG001","value":"-0.2","spread":"5.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"4.11"},{"groupId":"OG001","value":"-1.7","spread":"4.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"13.48"},{"groupId":"OG001","value":"-0.5","spread":"4.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"5.72"},{"groupId":"OG001","value":"-3.2","spread":"3.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"14.92"},{"groupId":"OG001","value":"0.2","spread":"4.17"}]}]}]},{"type":"SECONDARY","title":"Time to Definitive Deterioration in World Health Organization (WHO) Performance Status (PS) Change","description":"WHO PS is a scale rated from 0 (fully active) to 5 (death) by a healthcare professional to assess the overall status of a patient: a lower score represents a higher ability to perform daily tasks. Deterioration is defined as an increase of at least one point compared to baseline. Deterioration is considered definitive if no improvements in the WHO PS status is observed at a subsequent time of measurement during the treatment period following the time point where the deterioration is observed. Death was considered as worsening of the WHO PS if it occurred close to the last available assessment, where \"close\" was defined as twice the planned period between two assessments. Patients without definitive worsening prior to analysis cut-off or prior to start of another anticancer therapy were censored at the date of their last assessment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.08","spread":null},{"groupId":"OG001","value":"24.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29","description":"A pre-dose blood sample at day 29 was collected to determine the exposure of everolimus at the steady-state pre-dose concentration (Cmin). Cmin is provided for participants randomized to everolimus+BSC who received 10mg of everolimus daily and also for participants randomized to everolimus+BSC who received 5mg of everolimus daily which was required for a number of participants in the study experiencing adverse events requiring dose modifications","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.382","spread":"13.2767"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.700","spread":"3.8396"}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"Deaths on-treatment were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approximately 8 years.\n\nTotal Deaths were collected from first dose of study treatment until end of post-treatment survival follow, up to maximum duration of approximately 8 years.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"127","spread":null},{"groupId":"OG003","value":"57","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":93,"n":202},"commonTop":["Stomatitis","Diarrhoea","Fatigue","Oedema peripheral","Cough"]}}}